Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Medicines (SHSE:600511) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
China National Medicines Forward PE Ratio Related Terms
China National Medicines Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines Forward PE Ratio Chart
China National Medicines Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
11.05
10.16
China National Medicines Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
11.05
10.76
10.43
10.10
10.16
10.41
9.24
SHSE:600511 vs MCK, COR, CAH: Forward PE Ratio Comparison
For the Medical Distribution subindustry, China National Medicines's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines Forward PE Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where China National Medicines's Forward PE Ratio falls into.
China National Medicines Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
China National Medicines (SHSE:600511) has a Forward PE Ratio of 9.63 as of Aug. 29, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on China National Medicines and its competitors. According to the industry distribution chart, China National Medicines ranks #13 out of 50 companies in the Medical Distribution industry, placing it in the top 26%.
Is China National Medicines' Forward PE Ratio too high?
China National Medicines' current Forward PE Ratio is 9.63. The Medical Distribution industry median Forward PE Ratio is 14.46. China National Medicines' value of 9.63 is 33.4% below this industry median. Based on the distribution chart, China National Medicines ranks #13 out of 50 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Forward PE Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #13 out of 50 companies for Forward PE Ratio. This puts China National Medicines in the upper half of its industry. The industry median Forward PE Ratio is 14.46. China National Medicines' value of 9.63 is 33.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Distribution company?
The median Forward PE Ratio among Medical Distribution companies is 14.46, based on 50 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China National Medicines's current Forward PE Ratio of 9.63 is 33.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on China National Medicines and its competitors. For the Medical Distribution industry, the median Forward PE Ratio is 14.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current Forward PE Ratio is 9.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Forward PE Ratio is 9.63 and 33.4% below the Medical Distribution industry median of 14.46. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Forward PE Ratio is 9.63 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Forward PE Ratio: 9.63
GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
Industry Position: 33.4% below the Medical Distribution median (#13 of 50)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score
Get the complete analysis for SHSE:600511
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
